DIAGNOS Announces Amendments to Convertible Debentures and Stock Warrants

Executive Summary

• Diagnos Inc. announced amendments to its $510,000 unsecured convertible debentures, extending maturity to March 1 2027 and lowering the conversion price from $0.38 to $0.32 while maintaining a 10% annual interest rate.
• The company also extended the expiry of 8,333,333 stock warrants (exercise price $0.40) from March 20 2026 to September 5 2026.
• Both amendments remain subject to TSX Venture Exchange approval and will be formalized through execution of documentation.

Key Details

• Debenture Amendment
• Original aggregate amount: $510,000 unsecured convertible debentures.
• Maturity date extended from March 1 2026 to March 1 2027.
• Conversion price reduced from $0.38 per share to $0.32 per share.
• Annual interest rate remains at 10% for the extended period (Mar 1 2026 – Mar 1 2027).
• All other terms unchanged.
• Related Party Disclosure
• Insider André Larente holds 2 debentures with a nominal aggregate value of $20,000.
• Amendment exempt from MI 61‑101 valuation and minority approval requirements (fair market value < 25% of market cap).
• Warrant Extension
• 8,333,333 stock warrants issued in the September 20 2024 private placement.
• Original expiry: March 20 2026; extended to September 5 2026.
• Exercise price unchanged at $0.40 per common share.
• Regulatory Conditions
• Amendments subject to acceptance by the TSX Venture Exchange and execution of formal documentation.
• Company will issue a follow‑up press release only if the Exchange rejects any amendment.

Notable Quotes

(No direct quotes were provided in the release.)